Scholar Rock Holding Corp
$ 47.80
-4.32%
20 Apr - close price
- Market Cap 5,739,559,000 USD
- Current Price $ 47.80
- High / Low $ 49.69 / 47.70
- Stock P/E N/A
- Book Value 2.26
- EPS -3.29
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.23 %
- 52 Week High 51.62
- 52 Week Low 27.07
About
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$57.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-14 | 2025-08-06 | 2025-05-05 | 2025-03-17 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.88 | -0.9 | -0.98 | -0.67 | -0.61 | -0.6644 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 | -0.49 |
| Estimated EPS | -0.8983 | -0.84 | -0.66 | -0.7076 | -0.6288 | -0.6 | -0.61 | -0.51 | -0.49 | -0.52 | -0.56 | -0.58 |
| Surprise | 0.0183 | -0.06 | -0.32 | 0.0376 | 0.0188 | -0.0644 | 0.01 | -0.08 | -0.01 | -0.01 | 0.09 | 0.09 |
| Surprise Percentage | 2.0372% | -7.1429% | -48.4848% | 5.3137% | 2.9898% | -10.7333% | 1.6393% | -15.6863% | -2.0408% | -1.9231% | 16.0714% | 15.5172% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2026-04-20 22:09:21
Akshay Vaishnaw, President of Research & Development at Scholar Rock Holding Corp (NASDAQ:SRRK), sold 12,246 shares of company stock for approximately $607,089. This "sell to cover" transaction was mandated to meet tax withholding obligations from restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Mr. Vaishnaw still holds a significant number of shares and RSUs in the company.
2026-04-20 22:09:21
Scholar Rock Holding Corp COO Keith Woods sold 10,220 shares of common stock for $49.5745 per share. This sale was a mandatory "sell to cover" transaction to fulfill tax withholding obligations from vesting restricted stock units (RSUs) on April 15, 2026, and was not a discretionary trade. After the transaction, Woods directly holds 620,055 shares and retains significant RSU holdings, aligning his compensation with the company's future performance.
2026-04-20 22:09:21
Scholar Rock COO Keith Woods sold 10,220 shares of company stock for approximately $506,651, primarily to cover tax obligations related to vesting restricted stock units. This transaction occurred as the stock trades near its 52-week high, and an InvestingPro analysis suggests the stock is currently overvalued. The company also recently resubmitted its Biologics License Application for apitegromab, a treatment for spinal muscular atrophy.
2026-04-20 22:09:21
Scholar Rock Holding Corp's CEO, David Hallal, sold 30,615 shares of common stock for $49.5745 per share on April 15, 2026. This "sell to cover" transaction was mandated to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and was not a discretionary trade. Following the sale, Hallal directly holds 1,639,034 shares and also has significant exposure through additional common stock and various RSU awards.
2026-04-20 22:09:21
Scholar Rock Holding Corp's CFO, Vikas Sinha, sold 10,410 shares of common stock at $49.5745 per share on April 16, 2026. This transaction was a mandatory "sell to cover" to fulfill tax withholding obligations from restricted stock units (RSUs) that vested on April 15, 2026, and was not a discretionary trade. After the sale, Sinha's equity position in the company totals 619,856 equity-linked interests.
2026-04-20 13:09:21
Scholar Rock announced inducement equity awards to nine new employees, covering 89,304 shares of common stock. These awards consist of stock options and restricted stock units, vesting over several years and are granted under the Company's 2022 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The grants serve as a material inducement for new hires to join Scholar Rock, a biopharmaceutical company focused on treatments for neuromuscular diseases.
